Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

How The Red-Hot Obesity Space Could Help Eli Lilly Join The 1,000 Club

Lilly's new weight-loss drug could top $62 billion in 2030 sales, an analyst said Friday as he boosted his price target on Eli Lilly stock to 1,000.

Investors Business Daily

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

20 Highest-Grossing Biotech Stocks: Giants Driving Innovation and Growth

Biotech stocks offers the potential for significant returns driven by breakthrough discoveries and advancements in healthcare, agriculture, and other industries.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Viking Therapeutics Catapults 121% As Weight-Loss Drug Beats Out Lilly's Zepbound

A weight-loss drug from Viking topped Lilly's Zepbound in a midstage study Tuesday. Viking stock more than doubled, while Lilly shares fell.

Investors Business Daily

Just 4 Stocks Account For Several Sectors' Outperformance

Nvidia stock gained 59% this year to help its sector beat the S&P 500's performance. Warren Buffett's Berkshire stock also lifted its sector.

Investors Business Daily

This Warren Buffett Stock Is On The Cusp Of Joining The $1 Trillion Club

Warren Buffett's Berkshire Hathaway is on the verge of reaching a $1 trillion market cap. These other stocks are next in line.

Investors Business Daily

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Weight-loss drug use could boost GDP in US by 1%, says Goldman Sachs

Weight-loss drug use could boost GDP in US by 1%, says Goldman Sachs

Some analysts predict market could reach $100bn a year by end of decade with Eli Lilly and Ozempic maker Novo Nordisk leading

The Guardian - US

3 Mega-Cap Stocks That Could Replace Tesla in the 'Magnificent Seven'

3 Mega-Cap Stocks That Could Replace Tesla in the 'Magnificent Seven'

As Tesla stock continues to underperform - now down more than 22% year-to-date - here are 3 mega-cap companies worthy of replacing the beleaguered EV giant in the elite group of mega-cap stocks known as the Magnificent Seven.

Europe's Most Valuable Stock Is a Must-Own Near 52-Week Highs

Europe's Most Valuable Stock Is a Must-Own Near 52-Week Highs

Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's stock market, too. Here's why NVO is a must-own stock.

Will Weight-Loss, Diabetes Drugs Drive LLY Stock Into $1 Trillion Club?

Will Weight-Loss, Diabetes Drugs Drive LLY Stock Into $1 Trillion Club?

Eli Lilly's weight-loss and diabetes drugs Zepbound and Mounjaro should drive the biopharma stock much higher, said a Morgan Stanley analyst.

Investors Business Daily

It's Not Too Late to Buy Eli Lilly Stock. Here's Why.

It's Not Too Late to Buy Eli Lilly Stock. Here's Why.

J.P. Morgan thinks sales of weight-loss drugs could exceed $100 billion by 2030. That's good news for Eli Lilly, which is now the largest pharma company by market capitalization and the 9th-biggest S&P 500 stock. Here's why LLY stock looks poised to put on even more weight in the months…

Warren Buffett And Disney Share A $543 Billion Moneymaking Secret

Warren Buffett And Disney Share A $543 Billion Moneymaking Secret

Think the Magnificent Seven stocks are only way to make money in the S&P 500? Warren Buffett and Walt Disney may beg to differ.

Investors Business Daily

Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review

Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review

The stock market rally hit fresh highs, with the S&P 500 hit 5,000. Arm and Palantir skyrocketed, with several other AI plays running higher.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Weight-loss drugs need to become cheaper, says AstraZeneca boss

Loss of muscle mass also flagged, as UK drugmaker works with China’s Eccogene on obesity and type 2 diabetes pill

Investors Business Daily

Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug

Viking Therapeutics moved up its timeline for an Eli Lilly-rivaling obesity treatment on Thursday, leading VKTX stock to a record high.

Novo Nordisk vs. Eli Lilly: Which Mega-Cap Healthcare Stock is a Better Buy for 2024?

Healthcare stocks LLY and NVO have crushed broader market returns in the past two decades. But with competition heating up over obesity drugs, which mega-cap stock is a better buy today?

Stock Market Today: Higher Close for Stocks, Palantir Soars on AI Optimism

While the main indexes made modest moves Tuesday, Palantir Technologies soared 30% after earnings.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Closes Higher As Dow Jones Leads; Palantir Soars 31%

The stock market made progress Tuesday afternoon. Nvidia finally took a break from all-time highs while Tesla closed strong.

Investors Business Daily

Dow Jones Rises As Tesla Stock Downgraded; Palantir Soars 25% On Surging AI Demand

The Dow Jones rose Tuesday, as Tesla stock slid on an analyst downgrade. Palantir stock soared 25% on surging AI demand.

Investors Business Daily

Why Lilly's New Weight-Loss Study Absolutely Crushed 89bio, Akero, Madrigal

Eli Lilly stock pulled back from bullish gains Tuesday despite strong weight-loss drug sales and a promising test in liver disease treatment.

Eli Lilly & Co. (LLY) Pre-Earnings Moves: Buy or Watch?

Eli Lilly (LLY) saw steady growth in its last reported quarter, driven by sales from its popular diabetes drug Mounjaro. The stock has had an impressive run over the past year. However, will the momentum be sustained following its upcoming earnings release scheduled for tomorrow? Read on.

Investors Business Daily

Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record

Amgen stock slumped Monday — as Eli Lilly stock hit a record high — after the company unveiled preclinical results for its weight-loss drug.

Top 3 Smart Pharma Picks for Good Investments

As global medical needs and technology evolve, the pharmaceutical industry is expected to thrive. Therefore, fundamentally strong pharma stocks Eli Lilly (LLY), AstraZeneca (AZN) and GSK (GSK) might be ideal additions to your portfolio. Read on.

Investors Business Daily

Forget The Magnificent Seven. Focus On These Fab Five.

Investors put a lot of attention on Nvidia and the rest of the Magnificent Seven. But two of these giants aren't nearly as fabulous.

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

243,973 stories

102,352 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play